{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-006866","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2022-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.479071+00:00","generated_at":"2026-06-26T02:11:06.757705+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Dyne Therapeutics Reports Q1 2022 Net Loss of $35.6M and Provides Clinical Milestones","bullets":["Net loss for Q1 2022 was $35.6 million ($0.69 per share) vs. $25.0 million in Q1 2021.","Cash, cash equivalents and marketable securities totaled $323.2 million as of March 31, 2022.","R&D expenses were $28.2 million in Q1 2022, up from $18.6 million in Q1 2021.","Company plans to submit IND response for DYNE-251 in DMD and regulatory filings for DYNE-101 in DM1 in Q2 2022.","Initiation of multiple ascending dose clinical trials for DYNE-251 and DYNE-101 anticipated in mid-2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-006866","json":"https://secwatch.observer/filing/0000950170-22-006866.json","markdown":"https://secwatch.observer/filing/0000950170-22-006866.md","text":"https://secwatch.observer/filing/0000950170-22-006866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000095017022006866/0000950170-22-006866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000095017022006866/dyn-20220502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T02:11:06.757705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}